vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and OLAPLEX HOLDINGS, INC. (OLPX). Click either name above to swap in a different company.
AVANOS MEDICAL, INC. is the larger business by last-quarter revenue ($180.9M vs $105.1M, roughly 1.7× OLAPLEX HOLDINGS, INC.). AVANOS MEDICAL, INC. runs the higher net margin — -0.7% vs -12.5%, a 11.7% gap on every dollar of revenue. On growth, OLAPLEX HOLDINGS, INC. posted the faster year-over-year revenue change (4.3% vs 0.7%). OLAPLEX HOLDINGS, INC. produced more free cash flow last quarter ($32.6M vs $21.3M). Over the past eight quarters, AVANOS MEDICAL, INC.'s revenue compounded faster (4.4% CAGR vs 3.1%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Olaplex Holdings, Inc. is a specialty beauty company developing and selling patented bond-repair hair care products. It runs three core segments: professional salon distribution, direct-to-consumer sales, and third-party retail, serving customers across North America, Europe, and Asia-Pacific with products that repair and protect damaged hair.
AVNS vs OLPX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $105.1M |
| Net Profit | $-1.3M | $-13.1M |
| Gross Margin | 47.5% | 68.0% |
| Operating Margin | 1.4% | -4.3% |
| Net Margin | -0.7% | -12.5% |
| Revenue YoY | 0.7% | 4.3% |
| Net Profit YoY | 99.7% | -48.9% |
| EPS (diluted) | $-0.02 | $-0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $105.1M | ||
| Q3 25 | $177.8M | $114.6M | ||
| Q2 25 | $175.0M | $106.3M | ||
| Q1 25 | $167.5M | $97.0M | ||
| Q4 24 | $179.6M | $100.7M | ||
| Q3 24 | $170.4M | $119.1M | ||
| Q2 24 | $171.7M | $103.9M | ||
| Q1 24 | $166.1M | $98.9M |
| Q4 25 | $-1.3M | $-13.1M | ||
| Q3 25 | $-1.4M | $11.1M | ||
| Q2 25 | $-76.8M | $-7.7M | ||
| Q1 25 | $6.6M | $465.0K | ||
| Q4 24 | $-397.3M | $-8.8M | ||
| Q3 24 | $4.3M | $14.8M | ||
| Q2 24 | $1.8M | $5.8M | ||
| Q1 24 | $-900.0K | $7.7M |
| Q4 25 | 47.5% | 68.0% | ||
| Q3 25 | 48.4% | 69.1% | ||
| Q2 25 | 52.6% | 71.2% | ||
| Q1 25 | 53.6% | 69.5% | ||
| Q4 24 | 54.6% | 66.3% | ||
| Q3 24 | 54.5% | 68.6% | ||
| Q2 24 | 55.7% | 69.7% | ||
| Q1 24 | 57.1% | 72.1% |
| Q4 25 | 1.4% | -4.3% | ||
| Q3 25 | 0.1% | 3.7% | ||
| Q2 25 | -42.6% | -1.1% | ||
| Q1 25 | 6.1% | 8.7% | ||
| Q4 24 | -233.0% | 3.0% | ||
| Q3 24 | 7.0% | 23.5% | ||
| Q2 24 | 3.7% | 15.7% | ||
| Q1 24 | 2.4% | 19.8% |
| Q4 25 | -0.7% | -12.5% | ||
| Q3 25 | -0.8% | 9.7% | ||
| Q2 25 | -43.9% | -7.3% | ||
| Q1 25 | 3.9% | 0.5% | ||
| Q4 24 | -221.2% | -8.7% | ||
| Q3 24 | 2.5% | 12.4% | ||
| Q2 24 | 1.0% | 5.6% | ||
| Q1 24 | -0.5% | 7.8% |
| Q4 25 | $-0.02 | $-0.02 | ||
| Q3 25 | $-0.03 | $0.02 | ||
| Q2 25 | $-1.66 | $-0.01 | ||
| Q1 25 | $0.14 | $0.00 | ||
| Q4 24 | $-8.64 | $-0.01 | ||
| Q3 24 | $0.09 | $0.02 | ||
| Q2 24 | $0.04 | $0.01 | ||
| Q1 24 | $-0.02 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $318.7M |
| Total DebtLower is stronger | $90.3M | $352.3M |
| Stockholders' EquityBook value | $778.2M | $879.4M |
| Total Assets | $1.1B | $1.5B |
| Debt / EquityLower = less leverage | 0.12× | 0.40× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $318.7M | ||
| Q3 25 | $70.5M | $286.4M | ||
| Q2 25 | $90.3M | $289.3M | ||
| Q1 25 | $97.0M | $580.9M | ||
| Q4 24 | $107.7M | $586.0M | ||
| Q3 24 | $89.0M | $538.8M | ||
| Q2 24 | $92.2M | $507.9M | ||
| Q1 24 | $75.8M | $507.5M |
| Q4 25 | $90.3M | $352.3M | ||
| Q3 25 | $93.4M | $352.1M | ||
| Q2 25 | $95.7M | $351.9M | ||
| Q1 25 | $98.0M | $649.1M | ||
| Q4 24 | $125.3M | $650.5M | ||
| Q3 24 | $152.6M | $651.8M | ||
| Q2 24 | $164.9M | $653.1M | ||
| Q1 24 | $167.2M | $654.4M |
| Q4 25 | $778.2M | $879.4M | ||
| Q3 25 | $778.0M | $888.7M | ||
| Q2 25 | $776.3M | $874.2M | ||
| Q1 25 | $839.4M | $878.3M | ||
| Q4 24 | $828.5M | $874.4M | ||
| Q3 24 | $1.2B | $879.7M | ||
| Q2 24 | $1.2B | $863.3M | ||
| Q1 24 | $1.2B | $855.7M |
| Q4 25 | $1.1B | $1.5B | ||
| Q3 25 | $1.1B | $1.5B | ||
| Q2 25 | $1.0B | $1.5B | ||
| Q1 25 | $1.1B | $1.8B | ||
| Q4 24 | $1.2B | $1.8B | ||
| Q3 24 | $1.7B | $1.8B | ||
| Q2 24 | $1.7B | $1.8B | ||
| Q1 24 | $1.7B | $1.8B |
| Q4 25 | 0.12× | 0.40× | ||
| Q3 25 | 0.12× | 0.40× | ||
| Q2 25 | 0.12× | 0.40× | ||
| Q1 25 | 0.12× | 0.74× | ||
| Q4 24 | 0.15× | 0.74× | ||
| Q3 24 | 0.12× | 0.74× | ||
| Q2 24 | 0.13× | 0.76× | ||
| Q1 24 | 0.14× | 0.76× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $32.7M |
| Free Cash FlowOCF − Capex | $21.3M | $32.6M |
| FCF MarginFCF / Revenue | 11.8% | 31.0% |
| Capex IntensityCapex / Revenue | 3.8% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $58.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $32.7M | ||
| Q3 25 | $14.0M | $8.0M | ||
| Q2 25 | $6.8M | $20.9M | ||
| Q1 25 | $25.7M | $-2.9M | ||
| Q4 24 | $57.9M | $49.7M | ||
| Q3 24 | $23.0M | $33.5M | ||
| Q2 24 | $27.8M | $16.2M | ||
| Q1 24 | $-8.0M | $43.7M |
| Q4 25 | $21.3M | $32.6M | ||
| Q3 25 | $7.0M | $7.9M | ||
| Q2 25 | $-4.2M | $20.8M | ||
| Q1 25 | $19.0M | $-3.0M | ||
| Q4 24 | $53.1M | $49.2M | ||
| Q3 24 | $20.0M | $33.3M | ||
| Q2 24 | $21.9M | $16.1M | ||
| Q1 24 | $-12.1M | $43.3M |
| Q4 25 | 11.8% | 31.0% | ||
| Q3 25 | 3.9% | 6.9% | ||
| Q2 25 | -2.4% | 19.6% | ||
| Q1 25 | 11.3% | -3.1% | ||
| Q4 24 | 29.6% | 48.9% | ||
| Q3 24 | 11.7% | 28.0% | ||
| Q2 24 | 12.8% | 15.5% | ||
| Q1 24 | -7.3% | 43.7% |
| Q4 25 | 3.8% | 0.1% | ||
| Q3 25 | 3.9% | 0.1% | ||
| Q2 25 | 6.3% | 0.1% | ||
| Q1 25 | 4.0% | 0.0% | ||
| Q4 24 | 2.7% | 0.4% | ||
| Q3 24 | 1.8% | 0.1% | ||
| Q2 24 | 3.4% | 0.1% | ||
| Q1 24 | 2.5% | 0.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.72× | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | -6.27× | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | 2.26× | ||
| Q2 24 | 15.44× | 2.81× | ||
| Q1 24 | — | 5.64× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
OLPX
| Sales Channel Directly To Consumer | $43.6M | 42% |
| Sales Channel Through Intermediary Professional | $36.8M | 35% |
| Sales Channel Through Intermediary Specialty Retail | $24.7M | 23% |
